amcure, a spin-off from the Karlsruhe Institute of Technology, develops a first-in-class approach for the treatment of metastatic cancers. Our allosteric inhibitors are unique in that they show significant efficacy in relevant POC animal studies against highly metastatic epithelial cancers. Our peptide-based compounds target the tumor specific co-receptor CD44v6. Complex formation with CD44v6 is a prerequisite for the activation of several receptor tyrosine kinases (RTKs) that are instrumental for angiogenesis and metastasis (e.g. VEGFR-2 and c-Met). The mode of action of our approach differs fundamentally from known experimental or approved compounds in this area, which in most cases either address only a single RTK or target multiple RTKs as broadband inhibitors. By targeting CD44v6 our compounds combine the advantages of receptor specificity and broadband inhibition.
View Top Employees from amcure GmbHWebsite | http://www.amcure.com |
Revenue | $2 million |
Employees | 5 (4 on RocketReach) |
Founded | 2011 |
Phone | +49 7247 9342490 |
Technologies |
JavaScript,
HTML,
PHP
+6 more
(view full list)
|
Industry | Biotechnology Research, Business Services General, Biotechnology, Business Services, Science and Engineering, Health Care, Therapeutics |
Web Rank | 16 Million |
SIC | SIC Code 87 Companies, SIC Code 873 Companies |
NAICS | NAICS Code 54171 Companies, NAICS Code 541713 Companies, NAICS Code 5417 Companies, NAICS Code 541 Companies, NAICS Code 54 Companies |
Looking for a particular amcure GmbH employee's phone or email?
The amcure GmbH annual revenue was $2 million in 2024.
4 people are employed at amcure GmbH.
The NAICS codes for amcure GmbH are [54171, 541713, 5417, 541, 54].
The SIC codes for amcure GmbH are [87, 873].